Literature DB >> 8957519

FGFR2 mutation in clinically nonclassifiable autosomal dominant craniosynostosis with pronounced phenotypic variation.

D Steinberger1, T Reinhartz, R Unsöld, U Müller.   

Abstract

We describe a mutation in the FGFR2 gene in affected members of a large family with inherited autosomal dominant craniosynostosis. The mutation is a G1044A transition at codon 344 of exon B of the gene and results in abnormal splicing of the FGFR2 transcript. The phenotypic effect of the mutation varies greatly. It ranges from minor anomalies such as slight hypertelorism and maxillary hypoplasia to severe manifestations such as brachycephaly and dolichocephaly. The severe cases required surgery because of increased intracranial pressure. The patients cannot be assigned clinically to one of the known craniosynostotic syndromes with mutations in FGFR2, e.g., Crouzon, Pfeiffer, or Jackson-Weiss. This study demonstrates that FGFR2 mutations can result in a spectrum of craniofacial abnormalities even within one family. The known eponymic syndromes of Crouzon, Pfeiffer, or Jackson-Weiss only describe phenotypic extremes of this spectrum. Therefore, the clinical classification should be abandoned and replaced by a molecular one such as "FGFR-associated craniosynostosis syndromes."

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957519     DOI: 10.1002/(SICI)1096-8628(19961202)66:1<81::AID-AJMG19>3.0.CO;2-M

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  9 in total

Review 1.  Molecular genetics of craniosynostotic syndromes.

Authors:  U Müller; D Steinberger; S Kunze
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-09       Impact factor: 3.117

2.  Expression of FGFR-2 and FGFR-3 in the normal human fetal orbit.

Authors:  S H Khan; J A Britto; R D Evans; K K Nischal
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

3.  Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.

Authors:  Shih-hsin Kan; Navaratnam Elanko; David Johnson; Laura Cornejo-Roldan; Jackie Cook; Elsa W Reich; Susan Tomkins; Alain Verloes; Stephen R F Twigg; Sahan Rannan-Eliya; Donna M McDonald-McGinn; Elaine H Zackai; Steven A Wall; Maximilian Muenke; Andrew O M Wilkie
Journal:  Am J Hum Genet       Date:  2002-01-04       Impact factor: 11.025

4.  Anomalous extraocular muscles in Crouzon syndrome with V-pattern exotropia.

Authors:  Seung Ah Chung; Seung Yeop Lee
Journal:  Indian J Ophthalmol       Date:  2020-05       Impact factor: 1.848

5.  A novel mutation (a886g) in exon 5 of FGFR2 in members of a family with Crouzon phenotype and plagiocephaly.

Authors:  D Steinberger; H Collmann; B Schmalenberger; U Müller
Journal:  J Med Genet       Date:  1997-05       Impact factor: 6.318

6.  Central nervous system phenotypes in craniosynostosis.

Authors:  Kristina Aldridge; Jeffrey L Marsh; Daniel Govier; Joan T Richtsmeier
Journal:  J Anat       Date:  2002-07       Impact factor: 2.610

7.  Visual outcomes and amblyogenic risk factors in craniosynostotic syndromes: a review of 141 cases.

Authors:  S H Khan; K K Nischal; F Dean; R D Hayward; J Walker
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

8.  Molecular analysis of FGFR 2 and associated clinical observations in two Chinese families with Crouzon syndrome.

Authors:  Ying Lin; Hongbin Gao; Siming Ai; Jacob V P Eswarakumar; Tao Li; Bingqian Liu; Hongye Jiang; Yuhua Liu; Xialin Liu; Yonghao Li; Yao Ni; Jiangna Chen; Zhuoling Lin; Xiaoling Liang; Chenjin Jin; Xinhua Huang; Lin Lu; Yizhi Liu
Journal:  Mol Med Rep       Date:  2016-07-11       Impact factor: 2.952

9.  Mother and Daughter Carrying of the Same Pathogenic Variant in FGFR2 with Discordant Phenotype.

Authors:  Filomena Lo Vecchio; Elisabetta Tabolacci; Veronica Nobile; Maria Grazia Pomponi; Roberta Pietrobono; Giovanni Neri; Simona Amenta; Ettore Candida; Cristina Grippaudo; Ettore Lo Cascio; Alessia Vita; Federica Tiberio; Alessandro Arcovito; Wanda Lattanzi; Maurizio Genuardi; Pietro Chiurazzi
Journal:  Genes (Basel)       Date:  2022-06-27       Impact factor: 4.141

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.